Literature DB >> 6324457

Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen.

M Kishishita, J Luka, B Vroman, J F Poduslo, G R Pearson.   

Abstract

A monoclonal antibody designated L2 was produced against a late intracellular protein induced by Epstein-Barr virus (EBV). This protein was expressed in cells producing virus but not in EBV genome-positive nonproducer cell lines, EBV genome-negative cell lines, or producer cultures cultivated in the presence of phosphonoacetic acid as determined by immunofluorescence. In addition, the antibody did not react with the membranes of infected cells indicating that it was not directed against an EBV-induced membrane antigen component. The monoclonal antibody was shown to recognize a glycoprotein with a molecular weight of approximately 125K by SDS-polyacrylamide gel electrophoresis. This glycoprotein was consistently found to be slightly larger when isolated from the P3HR-1 cell line as opposed to the B-95-8 cell line. A similar difference was also noted by comparison of peptide maps of this protein isolated by immunoaffinity chromatography from the two cell lines. Serological studies indicated that this 125K glycoprotein was a major component of the viral capsid-antigen (VCA) complex as defined by immunofluorescence.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324457     DOI: 10.1016/0042-6822(84)90402-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.

Authors:  Susan M Turk; Ru Jiang; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro.

Authors:  S Swaminathan; B Tomkinson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

4.  Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.

Authors:  J Luka; G Miller; H Jörnvall; G R Pearson
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

5.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

6.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

7.  An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

Authors:  C L Miller; J H Lee; E Kieff; R Longnecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis.

Authors:  Jessica J Reimer; Marija Backovic; Charuhas G Deshpande; Theodore Jardetzky; Richard Longnecker
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

9.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C.

Authors:  A H Davies; R J Grand; F J Evans; A B Rickinson
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.